Literature DB >> 7518312

Clinical application of nebulized opioids for treatment of dyspnoea in patients with malignant disease.

M Farncombe1, S Chater.   

Abstract

This article describes our experience in the clinical use of nebulized opioids for the management of dyspnoea in patients with terminal cancer by reviewing three specific patient case studies in which this treatment was found to be both safe and effective in controlling breathlessness. The patients were treated with morphine, hydromorphone or anileridine in various doses according to their prior use of opioids. Additional formal studies are being initiated at this Centre.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7518312     DOI： 10.1007/bf00417478

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  14 in total

1.  Long-term management of respiratory symptoms in advanced cancer.

Authors:  K Cowcher; G W Hanks
Journal:  J Pain Symptom Manage       Date:  1990-10       Impact factor: 3.612

2.  Opioid inhibition of neurally mediated mucus secretion in human bronchi.

Authors:  D F Rogers; P J Barnes
Journal:  Lancet       Date:  1989-04-29       Impact factor: 79.321

3.  Opioid modulation of non-cholinergic neural bronchoconstriction in guinea-pig in vivo.

Authors:  M G Belvisi; K F Chung; D M Jackson; P J Barnes
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

4.  Inhaled nebulised morphine and diamorphine: useful in general practice?

Authors:  N Masters; G Heap; J Wedly; A Moore
Journal:  Practitioner       Date:  1988-09-08

5.  Case studies outlining use of nebulized morphine for patients with end-stage chronic lung and cardiac disease.

Authors:  M Farncombe; S Chater
Journal:  J Pain Symptom Manage       Date:  1993-05       Impact factor: 3.612

6.  Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease.

Authors:  I H Young; E Daviskas; V A Keena
Journal:  Thorax       Date:  1989-05       Impact factor: 9.139

7.  Dyspnea in terminally ill cancer patients.

Authors:  D B Reuben; V Mor
Journal:  Chest       Date:  1986-02       Impact factor: 9.410

8.  Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases.

Authors:  A A Woodcock; E R Gross; A Gellert; S Shah; M Johnson; D M Geddes
Journal:  N Engl J Med       Date:  1981-12-31       Impact factor: 91.245

9.  Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease.

Authors:  R W Light; J R Muro; R I Sato; D W Stansbury; C E Fischer; S E Brown
Journal:  Am Rev Respir Dis       Date:  1989-01

10.  Dihydrocodeine for breathlessness in "pink puffers".

Authors:  M A Johnson; A A Woodcock; D M Geddes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-02-26
View more
  1 in total

1.  Effect of hydromorphone on ventilation in palliative care patients with dyspnea.

Authors:  Katri Elina Clemens; Eberhard Klaschik
Journal:  Support Care Cancer       Date:  2007-10-11       Impact factor: 3.603
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.